The FDA has approved the vaccine Gardasil for the prevention of vaginal and vulvar cancer caused by human papillomavirus (HPV) types 16 and 18 in girls and women aged 9 to 26 years.
Medscape Medical News

continue reading.....

Durham University spin-out company Reinnervate, which is revolutionising the way cells are grown in the laboratory, is preparing for commercial manufacture and global sales after securing 750,000 pounds funding in a deal led by NorthStar Equity Investors (NSEI), a venture capital firm specialising in early-stage high-growth technologies.

continue reading.....

Among patients with stage 4 non-small-cell lung cancer who were positive for EGFR mutations, erlotinib was shown to increase overall survival.
Medscape Medical News

continue reading.....

Mars Petcare US announced a voluntary recall of products manufactured at its Everson, Pennsylvania facility. The pet food is being voluntarily recalled because of potential contamination with Salmonella serotypeSchwarzengrund. This voluntary recall only affects the United States.

continue reading.....

The NIH has awarded $9 million to launch a unique collaboration of researchers, clinicians, patients, government research agencies and pharmaceutical/biomedical companies to study the causes and potential treatments for facioscapulohumeral muscular dystrophy (FSHD), a muscle weakening and disabling disease that affects, at the least, one in 20,000 individuals worldwide. The award will create the first Senator Wellstone Muscular Dystrophy Cooperative Research Center (MD CRC) to focus on FSHD.

continue reading.....

Transition Therapeutics Inc. (”Transition” or the “Company”) (NASDAQ:TTHI, TSX:TTH) announced that the first patient has been dosed in a Phase 2 clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a 6-month follow-up.

continue reading.....

Acologix, Inc., a privately held biopharmaceutical company, announced the results of two preclinical studies demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein produced by bone and dental cells, promotes cartilage regeneration in large animal models. The data will be presented by Dr. Catherine A.

continue reading.....

Bionovo, Inc. (Nasdaq: BNVI) announced the publishing of a paper in the journal for the American Society for Pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, entitled “Oxidative In Vitro Metabolism of Liquiritigenin, a Bioactive Compound Isolated from the Chinese Herbal Selective Estrogen Beta-Receptor Agonist MF101.

continue reading.....

Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry.

continue reading.....